Champions Oncology (NASDAQ:CSBR) Shares Pass Below Two Hundred Day Moving Average – Time to Sell?

Champions Oncology, Inc. (NASDAQ:CSBR)’s stock price passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $6.32 and traded as low as $5.65. Champions Oncology shares last traded at $5.65, with a volume of 895 shares.

Analysts Set New Price Targets

Separately, Weiss Ratings downgraded shares of Champions Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 22nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Champions Oncology has an average rating of “Sell”.

Champions Oncology Trading Down 1.9%

The stock’s fifty day moving average is $5.95 and its two-hundred day moving average is $6.32. The company has a market capitalization of $78.46 million, a PE ratio of -35.31 and a beta of 0.41.

Institutional Investors Weigh In On Champions Oncology

Several institutional investors have recently added to or reduced their stakes in the business. Mink Brook Asset Management LLC purchased a new stake in Champions Oncology during the fourth quarter valued at about $555,000. Essex Investment Management Co. LLC purchased a new stake in Champions Oncology during the fourth quarter valued at about $126,000. Vanguard Group Inc. lifted its holdings in Champions Oncology by 1.9% during the third quarter. Vanguard Group Inc. now owns 333,258 shares of the biotechnology company’s stock valued at $2,158,000 after purchasing an additional 6,229 shares during the last quarter. XTX Topco Ltd purchased a new stake in Champions Oncology during the second quarter valued at about $103,000. Finally, Acadian Asset Management LLC lifted its holdings in Champions Oncology by 28.7% during the first quarter. Acadian Asset Management LLC now owns 39,511 shares of the biotechnology company’s stock valued at $341,000 after purchasing an additional 8,814 shares during the last quarter. 41.30% of the stock is owned by hedge funds and other institutional investors.

About Champions Oncology

Champions Oncology, Inc engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients.